Top Page
3D Medicines, Inc.
(1244)
3D Medicines, Inc. (1244) vs. iShares MSCI Hong Kong ETF (EWH)
3D Medicines, Inc. Business Overview & Revenue Model
3D Medicines, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 445.65M | 634.95M | 567.39M | 60.26M | 0.00 |
| Gross Profit | 371.74M | 524.01M | 525.18M | 55.98M | 0.00 |
| EBITDA | -226.95M | -529.23M | -1.03B | -1.45B | -303.35M |
| Net Income | -182.66M | -524.70M | -1.02B | -1.43B | -635.38M |
Balance Sheet | |||||
| Total Assets | 1.22B | 1.43B | 1.33B | 1.06B | 496.22M |
| Cash, Cash Equivalents and Short-Term Investments | 840.98M | 996.58M | 942.03M | 824.48M | 414.26M |
| Total Debt | 237.62M | 282.43M | 175.70M | 58.74M | 20.37M |
| Total Liabilities | 512.54M | 558.20M | 436.65M | 3.33B | 1.77B |
| Stockholders Equity | 785.06M | 936.74M | 943.00M | -2.24B | -1.27B |
Cash Flow | |||||
| Free Cash Flow | -255.94M | -150.74M | -332.76M | -433.46M | -289.48M |
| Operating Cash Flow | -210.58M | -144.41M | -278.78M | -377.08M | -278.33M |
| Investing Cash Flow | 17.95M | -187.58M | -242.11M | -98.87M | -20.48M |
| Financing Cash Flow | -33.92M | 304.51M | 408.41M | 840.08M | 607.39M |
3D Medicines, Inc. Technical Analysis
3D Medicines, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | HK$2.05B | ― | -21.22% | ― | -31.34% | 67.95% | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
| ― | €156.57M | ― | -14.48% | ― | ― | ― | |
| ― | €273.31M | ― | -4.30% | ― | ― | ― | |
71 Outperform | HK$1.68B | 211.43 | 0.99% | ― | 9.41% | -32.69% | |
54 Neutral | HK$2.51B | ― | -41.34% | ― | -10.78% | 24.88% | |
53 Neutral | HK$1.62B | ― | -32.59% | ― | -79.65% | 37.50% |
3D Medicines, Inc. Corporate Events
3D Medicines Inc., incorporated in the Cayman Islands, announced the withdrawal of civil proceedings initiated by Qingdao Hainuo against the company. The court approved the withdrawal, and Qingdao Hainuo will bear the associated fees of approximately RMB1.17 million. This development removes a potential legal hurdle for 3D Medicines, potentially stabilizing its market position and reassuring stakeholders.
3D Medicines Inc. has announced a strategic cooperation agreement with Qingdao Hainuo, aimed at resolving ongoing legal disputes and fostering future collaboration. The agreement, valued at RMB98.0 million, led to the withdrawal of civil proceedings and the discharge of a Preservation Order, thereby enhancing the company’s operational and financial stability.
3D Medicines, Inc. has entered into a Strategic Cooperation Agreement with Qingdao Hainuo, a substantial shareholder of its subsidiary, to discharge a Preservation Order imposed by the Qingdao Intermediate People’s Court. This agreement, valued at RMB98.0 million, aims to improve the company’s financial flexibility and operational efficiency by unfreezing bank accounts and facilitating smoother day-to-day operations, thereby reinforcing the company’s financial stability.
3D Medicines Inc. announced the successful passing of all resolutions at its Annual General Meeting held on June 30, 2025. Key resolutions included the appointment of Mr. Zhu Jinqiao as a non-executive director and the re-election of independent directors, along with the authorization for the board to manage share allotments and repurchases. These developments are poised to impact the company’s governance structure and operational strategies positively.
3D Medicines Inc. has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board has also established three committees: Audit, Remuneration, and Nomination, with specific directors assigned as members or chairpersons of these committees. This organizational structure aims to enhance corporate governance and operational efficiency, potentially impacting the company’s strategic direction and stakeholder relations.
3D Medicines Inc. announced a change in its board of directors, with Mr. Zhu Pai retiring as a non-executive director to focus on other engagements. The board expressed gratitude for his contributions. Following his retirement, the company proposes appointing Mr. Zhu Jinqiao, who has extensive experience in investment and entrepreneurship consulting, as the new non-executive director. This transition may influence the company’s strategic direction, given Mr. Zhu Jinqiao’s notable background and achievements in the healthcare investment sector.
3D Medicines Inc. has announced its upcoming annual general meeting scheduled for June 30, 2025, in Beijing, where shareholders will consider various resolutions, including the adoption of the 2024 financial statements and the election and re-election of directors. The meeting will also address the re-appointment of the company’s auditor and authorize the board to manage director remuneration and share allotments, indicating a focus on strengthening governance and operational oversight.